The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...
Researchers at the University of Toronto's Temerty Faculty of Medicine have found widespread genetic and protein changes in ...
SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the ...
There are hardly any drugs against ALS. A new study shows that a substance acting on the MAPK signaling pathway may be effective against the neurodegenerative disease: After treatment with trametinib, ...
SAN FRANCISCO, June 11, 2020 /PRNewswire-PRWeb/ -- Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all in-human genomic platform with ...
While drugs are on the market to slow the progression of neurodegenerative diseases, there are still no cures. But researchers at Boston Children’s Hospital and Harvard Medical School are looking for ...
The pathway leading to the telltale sign of ALS, protein aggregation in the cytoplasm of motor neurons, has been revealed. Researchers from the University of California – San Diego (CA, USA) have ...
Following the Food and Drug Administration’s recent decision to give the green light to aducanumab, the first treatment approved for Alzheimer’s disease in nearly two decades, the agency has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback